basiliximab + cyclosporine + mycophenolate sodium

This is a **combination immunosuppressive regimen** used primarily for the prevention of acute rejection in kidney transplantation. It consists of: - **Basiliximab**: a chimeric (murine/human) monoclonal antibody targeting the CD25 alpha chain (IL-2 receptor alpha) on activated T-lymphocytes, thereby blocking IL-2 mediated T-cell activation, a crucial step in the immune response against allograft tissue[2][4][6]. - **Cyclosporine**: a small molecule calcineurin inhibitor that suppresses T-cell activation by inhibiting the nuclear factor of activated T-cells (NFAT) pathway and reducing interleukin-2 (IL-2) transcription, leading to broad immunosuppression[1][5]. - **Mycophenolate sodium**: an enteric-coated formulation of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase (IMPDH) and suppresses guanine nucleotide synthesis, thereby preventing the proliferation of T and B lymphocytes[1][5]. This regimen is used as induction and maintenance therapy following kidney transplantation in order to reduce the risk of acute rejection, often in combination with corticosteroids. Basiliximab provides selective, non-depleting, temporary inhibition of T-cell activation. Cyclosporine and mycophenolate sodium provide continuous immunosuppression to prevent graft rejection. The regimen is characterized by a **multimodal, complementary mechanism of immunosuppression**[1][5].

Other names

mycophenolate sodium + basiliximab + cyclosporine